Synthesis and structure-activity relationships of cerebroside analogues as substrates of cerebroside sulphotransferase and discovery of a competitive inhibitor

References

• Köhler W, Curiel J, Vanderver A. Adulthood leukodystrophies. Nat Rev Neurol 2018;14:94–105.
   PubMed Web of Science ®Google Scholar
• Sessa M, Lorioli L, Fumagalli F, et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 2016;388:476–87.
   PubMed Web of Science ®Google Scholar
• Coutinho MF, Santos JI, Alves S. Less is more: substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci 2016;17:1065.
   Web of Science ®Google Scholar
• Gieselmann V, Krägeloh-Mann I. Metachromatic leukodystrophy – an update. Neuropediatrics 2010;41:1–6.
   PubMed Web of Science ®Google Scholar
• Honke K. Biological functions of sulfoglycolipids and the EMARS method for identification of co-clustered molecules in the membrane microdomains. J Biochem 2018;163:253–63.
   PubMed Web of Science ®Google Scholar
• Honke K. Biosynthesis and biological function of sulfoglycolipids. Proc Jpn Acad, Ser B, Phys Biol Sci 2013;89:129–38.
   PubMed Web of Science ®Google Scholar
• Eckhardt M. The role and metabolism of sulfatide in the nervous system. Mol Neurobiol 2008;37:93–103.
   PubMed Web of Science ®Google Scholar
• Yoshinari K, Petrotchenko EV, Pedersen LC, Negishi M. Crystal structure-based studies of cytosolic sulfotransferase. J Biochem Mol Toxicol 2001;15:67–75.
   PubMed Web of Science ®Google Scholar
• Negishi M, Pedersen LG, Petrotchenko E, et al. Structure and function of sulfotransferases. Arch Biochem Biophys 2001;390:149–57.
   PubMed Web of Science ®Google Scholar
• Superti-Furga A. A defect in the metabolic activation of sulfate in a patient with achondrogenesis type IB. Am J Hum Genet 1994;55:1137–45.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu Y, Sullards MC, Merrill AH Jr. An introduction to sphingolipid metabolism and analysis by new technologies. Neuromol Med 2010;12:306–19.
   PubMed Web of Science ®Google Scholar
• Rath VL, Verdugo D, Hemmerich S. Sulfotransferase structural biology and inhibitor discovery. Drug Discov Today 2004;9:1003–11.
   PubMed Web of Science ®Google Scholar
• Zaruba M, Hilt D, Tennekoon G. Inhibition of rat brain galactocerebroside sulfotransferase by triazine aromatic dyes: interaction with the 3'-phosphoadenosine 5'-phosphosulfate binding site. Biochem Biophys Res Commun 1985;129:522–9.
   PubMed Web of Science ®Google Scholar
• Pedersen LC, Petrotchenko E, Shevtsov S, Negishi M. Crystal structure of the human estrogen sulfotransferase-PAPS complex: evidence for catalytic role of Ser137 in the sulfuryl transfer reaction. J Biol Chem 2002;277:17928–32.
   PubMed Web of Science ®Google Scholar
• Edavettal SC, Lee KA, Negishi M, et al. Crystal structure and mutational analysis of heparan sulfate 3-O-sulfotransferase isoform 1. J Biol Chem 2004;279:25789–97.
   PubMed Web of Science ®Google Scholar
• Pedersen LC, Darden TA, Negishi M. Crystal structure of beta 1,3-glucuronyltransferase I in complex with active donor substrate UDP-GlcUA. J Biol Chem 2002;277:21869–73.
   PubMed Web of Science ®Google Scholar
• Copeland RA. Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists. Hoboken: John Wiley & Sons; 2005.
   Google Scholar
• Li W, Zech I, Gieselmann V, Müller CE. A capillary electrophoresis method with dynamic pH junction stacking for the monitoring of cerebroside sulfotransferase. J Chromatogr A 2015;1407:222–7.
   PubMed Web of Science ®Google Scholar
• Eckhardt M, Fewou SN, Ackermann I, Gieselmann V. N-glycosylation is required for full enzymic activity of the murine galactosylceramide sulphotransferase. Biochem J 2002;368:317–24.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Prusoff WH. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099–108. PMID 4202581.
   PubMed Web of Science ®Google Scholar
• Ding N, Zhang W, Lv G, Li Y. Synthesis and biological evaluation of antifungal activities of novel 1,2-trans glycosphingolipids. Arch Pharm (Weinheim) 2011;344:786–93.
   PubMed Web of Science ®Google Scholar
• Goff RD, Gao Y, Mattner J, et al. Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004;126:13602–3.
   PubMed Web of Science ®Google Scholar
• Li Q, Ndonye RM, Illarionov PA, et al. Rapid identification of immunostimulatory alpha-galactosylceramides using synthetic combinatorial libraries. J Comb Chem 2007;9:1084–93.
   PubMedGoogle Scholar
• Lim C, Kim JH, Baek DJ, et al. Design and evaluation of ω-hydroxy fatty acids containing α-GalCer analogues for CD1d-mediated NKT cell activation. ACS Med Chem Lett 2014;5:331–5.
   PubMed Web of Science ®Google Scholar
• Xia C, Yao Q, Schümann J, et al. Synthesis and biological evaluation of alpha-galactosylceramide (KRN7000) and isoglobotrihexosylceramide (iGb3). Bioorg Med Chem Lett 2006;16:2195–9.
   PubMed Web of Science ®Google Scholar
• Fujio M, Wu D, Garcia-Navarro R, et al. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc 2006;128:9022–3.
   PubMed Web of Science ®Google Scholar
• Guillaume J, Pauwels N, Aspeslagh S, et al. Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists. Bioorg Med Chem 2015;23:3175–82.
   PubMedGoogle Scholar
• Figueroa-Pérez S, Schmidt RR. Total synthesis of alpha-galactosyl cerebroside. Carbohydr Res 2000;328:95–102.
   PubMed Web of Science ®Google Scholar
• Schneiders FL, Scheper RJ, von Blomberg BM, et al. Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol 2011;140:130–41.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Horiguchi S, Kurosaki M, et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2011;138:255–65.
   PubMed Web of Science ®Google Scholar
• Washah H, Agoni C, Olotu FA, et al. Tweaking α-galactoceramides: probing the dynamical mechanisms of improved recognition for invariant natural killer T-cell receptor in cancer immunotherapeutics. Curr Pharm Biotechnol 2020; In Press.DOI:10.2174/1389201020666191118103342
   PubMed Web of Science ®Google Scholar